UCB SA (OTCMKTS:UCBJF) Short Interest Up 59.5% in November

UCB SA (OTCMKTS:UCBJF) was the recipient of a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 643,700 shares, an increase of 59.5% from the October 31st total of 403,500 shares. Based on an average trading volume of 200 shares, the days-to-cover ratio is presently 3,218.5 days.

UCB Stock Performance

OTCMKTS UCBJF opened at $174.00 on Friday. UCB has a fifty-two week low of $73.54 and a fifty-two week high of $194.76. The business has a 50 day moving average price of $180.94 and a two-hundred day moving average price of $160.30. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.